Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
This is a 59.1% decrease from the number of companies inspected in the previous year, when 22 companies were inspected through 22 inspections.
Most of the companies inspected were involved in the Drugs and Biologics sectors. The second most common type of company inspected in the time period worked in the Food/Cosmetics and Devices sectors.
There were seven companies in line with FDA regulations who don’t need to adjust their management operations or regulatory/administrative actions. Two should take voluntary action to correct the organization's management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Result |
---|---|---|---|
Elevation Foods, LLC | Food/Cosmetics | 04/07/2023 | No Action Indicated (NAI) |
Galbraith Laboratories, Inc. | Veterinary | 11/16/2023 | Voluntary Action Indicated (VAI) |
Jointvue, LLC | Devices | 07/07/2023 | No Action Indicated (NAI) |
National Embryo Donation Center | Biologics | 01/12/2023 | Voluntary Action Indicated (VAI) |
Neil E. Faulkner, M.D. | Drugs | 04/14/2023 | No Action Indicated (NAI) |
Southeastern Andrology and Embryology, LLC. | Biologics | 01/12/2023 | No Action Indicated (NAI) |
Tomato Head Foods | Food/Cosmetics | 01/25/2023 | No Action Indicated (NAI) |
University of Tennessee Graduate School of Medicine IRB | Biologics | 11/08/2023 | No Action Indicated (NAI) |
University of Tennessee Graduate School of Medicine IRB | Devices | 11/08/2023 | No Action Indicated (NAI) |
University of Tennessee Graduate School of Medicine IRB | Drugs | 11/08/2023 | No Action Indicated (NAI) |
William B Smith, M.D. | Drugs | 09/21/2023 | No Action Indicated (NAI) |